SPECIALTY QUANTITY LIMIT PROGRAM

REMICADE (infliximab) **INFLECTRA** (infliximab-dyyb) **RENFLEXIS** (infliximab-abda)

PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. If member's plan allows a quantity limit exception review for the requested medication, coverage of an additional quantity may be provided up to the exception limit with prior authorization.

II. COVERED QUANTITIES


Medication	Standard Limit	Exception Limit*	FDA-recommended dosing
Remicade (infliximab) injection 100 mg vial	10 vials per 28 days	Induction dose • Up to 100 kg: 30 vials per 42 days • Above 100 kg: up to 60 vials per 42 days Maintenance dose • Up to 20 vials per 4 weeks	Adult CD 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks (may increase the dose up to 10 mg/kg for loss of response)
Inflectra (infliximab-dyyb) injection 100 mg vial			 UC/PsA/Pediatric CD/Plaque psoriasis 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks RA 3 mg/kg at 0, 2 and 6 weeks, then every 8 weeks, in combination with methotrexate (may increase the dose up to 10 mg/kg or treat as often as every 4 weeks) AS 5 mg/kg at 0, 2 and 6 weeks, then every 6 weeks
Renflexis (infliximab-abda) injection 100 mg vial			

Abbreviations: RA = rheumatoid arthritis; PsA = psoriatic arthritis; AS = ankylosing spondylitis; CD = Crohn's disease; UC = ulcerative colitis * Coverage up to the exception limits may be provided with prior authorization via the Specialty Post Limit Quantity Exception Criteria for approval.

Specialty Quantity Limit Remicade-Inflectra-Renflexis 2274-H P2019

pharmaceutical manufacturers that are not affiliated with CVS Caremark.

© 2019 CVS Caremark. All rights reserved.



This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written

2274-H

III. REFERENCES

- 1. Remicade [package insert]. Horsham, PA: Janssen Biotech, Inc.; June 2018.
- Inflectra [package insert]. Lake Forest, IL: Hospira, a Pfizer Company; July 2018.
- 3. Renflexis [package insert]. Kenilworth, NJ. Merck &Co., Inc; November 2017.

DOCUMENT HISTORY

Specialty Clinical Development (JP) 08/2017 Created:

CN 08/2018, JC 08/2019 (annual) Revised:

Reviewed: CDPR/ ME 09/2017, ME 09/2018, CHART 8/29/2019

Rheumatology: 10/2017, 11/2018, 11/2019 External Review:

Dermatology: 11/2017, 10/2018, 11/2019 Gastroenterology: 11/2017, 10/2018, 11/2019

pharmaceutical manufacturers that are not affiliated with CVS Caremark.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written